Nuvation Bio Inc. — Q2 2023 Form 10-Q
Business context and reporting period
Clinical-stage oncology biopharmaceutical company; this unaudited filing covers the quarter and six months ended June 30, 2023. Nuvation Bio has no commercially approved products and reported no revenue.
Financial results and liquidity
| Metric | Three months ended June 30, 2023 | Six months ended June 30, 2023 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $18.6 million | $37.4 million |
| General and administrative expense | $7.5 million | $15.3 million |
| Operating loss | $26.1 million | $52.7 million |
| Interest income | $6.1 million | $11.1 million |
| Net loss | $20.6 million | $42.4 million |
| Basic and diluted loss per share | $0.09 | $0.19 |
At June 30, cash and cash equivalents were $50.1 million and marketable securities were $580.8 million; together, $630.9 million. Total current assets were $637.2 million, current liabilities $13.4 million, total liabilities $16.8 million, and stockholders’ equity $624.6 million. The filing reports no interest-bearing debt; liabilities primarily include leases, accrued expenses, payables and warrant liabilities.
Operating cash use in the first half was $36.8 million, versus $51.8 million in 2022. Investing activities used $14.7 million, mainly reflecting purchases of marketable securities net of sales; financing provided $0.4 million. Cash and cash equivalents declined by $51.0 million, to $50.1 million. The company reported an accumulated deficit of $309.4 million. Profit margins are not meaningful given the absence of revenue and ongoing losses.
Material changes versus the prior comparable period
- Q2 operating expenses fell $11.7 million year over year to $26.1 million; first-half expenses fell $13.4 million to $52.7 million.
- R&D expense declined $10.3 million in Q2 and $12.3 million in the first half, mainly because third-party research and manufacturing costs fell following termination of the NUV-422 program, alongside lower personnel costs from headcount reductions.
- G&A expense declined $1.4 million in Q2 and $1.1 million in the first half, with lower insurance, legal and other costs partly offset by higher personnel-related costs.
- Net loss narrowed to $20.6 million from $34.9 million in Q2 and to $42.4 million from $56.2 million for the first half. Higher interest income contributed to the improvement; warrant fair-value movements differed substantially from the prior year and affected comparability.
Outlook, commentary and risks
- Management expects continuing operating losses and negative operating cash flows. It believes existing cash, cash equivalents and marketable securities will fund commitments for at least 12 months after the financial statements were issued.
- NUV-868 Phase 1 monotherapy and Phase 1b combination studies were ongoing. The company expected to submit an IND for its first DDC platform clinical candidate by year-end 2023.
- The company cautions that clinical development, enrollment, regulatory approval and commercialization are uncertain and costly; it relies on third parties for clinical work and manufacturing. Additional capital may be required, and financing could dilute shareholders or require concessions on intellectual property or programs.
- Management attributed unrealized marketable-security losses primarily to interest-rate changes and reported no expected credit-loss allowance. It did not intend, and did not believe it would be required, to sell securities before recovery of amortized cost.
- The filing notes that three of five programs pursued in February 2022 had since been discontinued or deprioritized, including the lead program. NUV-422 development was discontinued after a uveitis safety signal.
- No pending significant legal proceedings were reported. Disclosure controls and procedures were assessed as effective at June 30, 2023.
Important facts for investors to verify
- Progress, enrollment and emerging safety or efficacy data from the ongoing NUV-868 trials, and whether the DDC IND was submitted as anticipated.
- Actual cash use and investment balances in subsequent filings; the 12-month runway estimate depends on operating-plan assumptions and development costs.
- Pipeline prioritization and the status of programs following NUV-422’s discontinuation and other program reductions.
- Potential dilution: 33.2 million options were outstanding at June 30, 2023; assess future equity awards and financing needs.
- Governance concentration: CEO David Hung holds all Class B shares and approximately 27% of total common shares, with significant voting and transaction rights described in the filing.